Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
Wall Street analysts are quite bullish about Intellia Therapeutics (NASDAQ: NTLA) stock. On average, they're estimating that it'll rise by around 157% within the next 12 months. In the context of the new bull market shaping up right now, it likely has a good shot of actually delivering what analysts are hoping to see.
Does that mean this stock's ascent is inevitable in the near term? Or is Wall Street getting ahead of itself?
Let's start by examining the case in favor of Intellia performing as the analysts expect. Before the close of 2024, the biotech will have two ongoing phase 3 clinical programs that aim to therapeutically, and potentially permanently, correct the genes responsible for a pair of heritable rare illnesses, transthyretin (ATTR) amyloidosis, and hereditary angioedema (HAE).
Source Fool.com
Intellia Therapeutics Inc Stock
We see a rather positive sentiment for Intellia Therapeutics Inc with 17 Buy predictions and 1 Sell predictions.
Based on the current price of 25.0 € the target price of 60 € shows a potential of 140.0% for Intellia Therapeutics Inc which would more than double the current price.